Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Sep 28, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 24,782 | -- | 60,218 | |
| Sep 30, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 4,064 | $2.29 | 167,268 | |
| Sep 30, 2020 | Chief Medical Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 4,064 | $14.51 | 163,204 | |
| Sep 30, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 4,064 | -- | 14,666 | |
| Oct 01, 2020 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | $5.96 | 870,813 | |
| Oct 01, 2020 | Director, Chairman & CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 29,900 | $14.02 | 840,913 | |
| Oct 01, 2020 | Director, Chairman & CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | -- | 23,975 | |
| Oct 01, 2020 | Chief Financial Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | $2.94 | 212,179 | |
| Oct 01, 2020 | Chief Financial Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 5,000 | $14.02 | 207,179 | |
| Oct 01, 2020 | Chief Financial Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 5,000 | -- | 33,128 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.